 Your new post is loading...
Your new post is loading...
|
Scooped by
Gilbert C FAURE
June 4, 1:31 PM
|
Out now! --> Cancer in a drop: Advances in liquid biopsy in 2024
An overview of all liquid biopsy studies published in 2024, done by the Young Committee of the International Society of Liquid Biopsy
https://lnkd.in/e-wgkYK8
Roberto Borea Eleonora Nicolò Letizia Pontolillo Diego de Miguel Perez Erick Saldanha Pasquale Pisapia Angelo Dipasquale Ana Ortega Franco Konstantinos Venetis Nadia Ghazali Christian Rolfo, MD, PhD, MBA,Dr.hc Umberto Malapelle Yüksel ÜRÜN Natasha Leighl Massimo Cristofanilli, MD, FACP Mª JOSE SERRANO Eloisa Jantus Nicola Fusco
|
|
Scooped by
Gilbert C FAURE
April 16, 3:54 AM
|
❤️ Hot off the press!
💫 Super excited to share our latest review just published in Nature Portfolio.
Liquid biopsies🩸, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring.
Circulating tumour DNA (#ctDNA) 🧬 and circulating tumour cells (#CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in #bladder #cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease (#MRD) and disease recurrence.
Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.
👏👏👏 Sia Viborg Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew Galsky, Tom Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières & Lars Dyrskjøt
🤩 Good reading !
CHU de Montpellier, Recherche et innovation – CHU de Montpellier, Renan Targhetta, Samir JABER
Liquid Biopsy LCCRH Lab - Laboratoire Cellules Circulantes Rares Humaines 🩸
Aarhus University
European Liquid Biopsy Society (ELBS)
PANCAID, GUIDE.MRD
OncoDaily | 11 comments on LinkedIn
|
|
Scooped by
Gilbert C FAURE
November 2, 2024 6:35 AM
|
🩸Liquid Biopsy Milestones since 1869 ...
✨Wonderful experience at the University of Technology Sydney (UTS) in #Australia.
CHU de Montpellier
Recherche et…
|
|
Scooped by
Gilbert C FAURE
February 2, 2024 8:18 AM
|
Global liquid biopsy for cancer diagnostics market size is expected to reach $16.42 Bn by 2028 at a rate of 15.7%, segmented as by type, product, services...
|
|
Scooped by
Gilbert C FAURE
April 11, 2023 4:34 AM
|
Over the last decade, liquid biopsy has gained much attention as a powerful tool in personalized medicine since it enables monitoring cancer evolution and follow-up of cancer patients in real time. Through minimally invasive procedures, liquid biopsy provides important information through the analysis of circulating tumour cells (CTCs) and circulating tumour-derived material, such as circulating tumour DNA (ctDNA), circulating miRNAs (cfmiRNAs) and extracellular vehicles (EVs). CTC analysis has already had an important impact on the prognosis, detection of minimal residual disease (MRD), treatment selection and monitoring of cancer patients. Numerous clinical trials nowadays include a liquid biopsy arm. CTC analysis is now an exponentially expanding field in almost all types of solid cancers. Functional studies, mainly based on CTC-derived cell-lines and CTC-derived explants (CDx), provide important insights into the metastatic process. The purpose of this review is to summarize the latest findings on the clinical significance of CTCs for the management of cancer patients, covering the last four years. This review focuses on providing a comprehensive overview of CTC analysis in breast, prostate and non-small-cell lung cancer. The unique potential of CTC single-cell analysis for understanding metastasis biology, and the importance of quality control and standardization of methodologies used in this field, is also discussed.
|
|
Scooped by
Gilbert C FAURE
August 9, 2022 1:52 PM
|
Over the past decade, various liquid biopsy techniques have emerged as viable alternatives to the analysis of traditional tissue biopsy samples. Such surrogate ‘biopsies’ offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on blood-based biomarkers, predominantly using plasma-derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non-blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various technical aspects of non-blood ctDNA assay development. We also reflect on the settings in which non-blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use. Advances in circulating tumour DNA (ctDNA) detection and analysis are beginning to be implemented in clinical practice. Nonetheless, much of this development has thus far focused on plasma ctDNA. Theoretically, all bodily fluids, including urine, cerebrospinal fluid, saliva, pleural fluid and others, can also contain measurable ctDNA and can provide several advantages over the reliance on plasma ctDNA. In this Review, Tivey et al. describe the potential roles of ctDNA obtained from non-plasma sources in optimizing the outcomes of patients with cancer.
|
|
Scooped by
Gilbert C FAURE
August 15, 2021 5:44 AM
|
Click on the article title to read more.
|
|
Scooped by
Gilbert C FAURE
April 3, 2021 11:53 AM
|
|
|
Scooped by
Gilbert C FAURE
October 16, 2020 2:23 PM
|
As we continue to better our understanding of cancer biology, one thing remains a game changer for cancer care: the ability to detect cancer in a liquid biopsy.Just a few years ago, the idea of hav...
|
|
Scooped by
Gilbert C FAURE
July 21, 2020 9:57 AM
|
The metastatic cascade describes the process whereby aggressive cancer cells leave the primary tumor, travel through the bloodstream, and eventually reach distant organs to develop one or several metastases. During the last decade, innovative technologies have exploited the recent biological knowledge to identify new circulating biomarkers for the screening and early detection of cancer, real-time monitoring of treatment response, assessment of tumor relapse risk (prognosis), identification of new therapeutic targets and resistance mechanisms, patient stratification, and therapeutic decision-making. These techniques are broadly described using the term of Liquid Biopsy. This field is in constant progression and is based on the detection of circulating tumor cells, circulating free nucleic acids (e.g., circulating tumor DNA), circulating tumor-derived extracellular vesicles, and tumor-educated platelets. The aim of this review is to describe the biological principles underlying the liquid biopsy concept and to discuss how functional studies can expand the clinical applications of these circulating biomarkers.
|
Suggested by
LIGHTING
March 30, 2020 4:49 AM
|
The analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis, says Catherine Alix-Panabières. The challenge now is to make liquid biopsy a standard clinical tool.
|
|
Scooped by
Gilbert C FAURE
March 25, 2020 4:03 PM
|
In the era of precision oncology, liquid biopsy techniques, especially the use of plasma circulating tumour DNA (ctDNA) analysis, represent a paradigm shift in the use of genomic biomarkers with considerable implications for clinical practice. Compared with tissue-based tumour DNA analysis, plasma ctDNA is more convenient to test, more readily accessible, faster to obtain and less invasive, minimizing procedure-related risks and offering the opportunity to perform serial monitoring. Additionally, genomic profiles of ctDNA have been shown to reflect tumour heterogeneity, which has important implications for the identification of resistant clones and selection of targeted therapy well before clinical and radiographic changes occur. Moreover, plasma ctDNA testing can also be applied to cancer screening, risk stratification and quantification of minimal residual disease. These features provide an unprecedented opportunity for early treatment of patients, improving the chances of treatment success. Liquid biopsy techniques, especially the use of plasma circulating tumour DNA (ctDNA) analysis, are a convenient, fast and non-invasive approach to the diagnosis and monitoring of urological cancers, and could enable selection of targeted therapy before clinical and radiographic changes occur. In this Review, the authors discuss the uses of liquid biopsy and plasma ctDNA analysis in particular, and consider how it could be used in clinical practice now and in the future.
|
|
Scooped by
Gilbert C FAURE
November 23, 2019 4:08 AM
|
Cancer originates from small mistakes in our DNA. These mistakes are different for every person and dictate how aggressive their cancer is.On top of this, starting in development and continuing throughout life, new mistakes in our DNA can be …...
|
|
|
Scooped by
Gilbert C FAURE
May 28, 3:35 AM
|
Fostering the Implementation of Liquid Biopsy in Clinical Practice: European Liquid Biopsy Society (ELBS) 2024 Meeting Report by Klaus Pantel et al.
Journal of Experimental & Clinical Cancer Research Catherine Alix-Panabières
https://lnkd.in/dag4Z7Vb
#Cancer #CancerResearch #LiquidBiopsy #Medicine #Health #Oncology #ELBS2024 #OncoDaily
|
|
Scooped by
Gilbert C FAURE
December 13, 2024 4:03 AM
|
|
|
Scooped by
Gilbert C FAURE
February 22, 2024 4:21 AM
|
|
|
Scooped by
Gilbert C FAURE
November 14, 2023 5:46 AM
|
The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic adenocarcinoma (PDAC) stems from their extremely low concentration in the whole circulating blood, necessitating enhanced detection methodologies. This study sought to amplify assay-sensitivity by employing diagnostic leukapheresis (DLA) to screen large blood volumes. Sixty patients were subjected to DLA, with a median processed blood volume of ~ 2.8 L and approximately 5% of the resulting DLA-product analyzed using CellSearch (CS). Notably, DLA significantly increased CS-CTC detection to 44% in M0-patients and 74% in M1-patients, yielding a 60-fold increase in CS-CTC enumeration. DLA also provided sufficient CS-CTCs for genomic profiling, thereby delivering additional genomic information compared to tissue biopsy samples. DLA CS-CTCs exhibited a pronounced negative prognostic impact on overall survival (OS), evidenced by a reduction in OS from 28.6 to 8.5 months (univariate: p = 0.002; multivariable: p = 0.043). Additionally, a marked enhancement in sensitivity was achieved (by around 3-4-times) compared to peripheral blood (PB) samples, with positive predictive values for OS being preserved at around 90%. Prognostic relevance of CS-CTCs in PDAC was further validated in PB-samples from 228 PDAC patients, consolidating the established association between CTC-presence and reduced OS (8.5 vs. 19.0 months, p < 0.001). In conclusion, DLA-derived CS-CTCs may serve as a viable tool for identifying high-risk PDAC-patients and aiding the optimization of multimodal treatment strategies. Moreover, DLA enables comprehensive diagnostic profiling by providing ample CTC material, reinforcing its utility as a reliable liquid-biopsy approach. This high-volume liquid-biopsy strategy presents a potential pathway for enhancing clinical management in this malignancy.
|
|
Scooped by
Gilbert C FAURE
September 25, 2022 4:17 AM
|
📚 Atlas of Liquid Biopsy Circulating Tumor Cells and Other Rare Cells in Cancer Patients’ Blood. Chapter 1, page 2. Ludmilla Thomé Domingos…
|
|
Scooped by
Gilbert C FAURE
September 27, 2021 3:26 AM
|
The liquid biopsy (LB) concept was introduced for circulating tumor cells (CTCs) 10 years ago (1) and rapidly extended to ctDNA (2) and other tumor-derived prod
|
|
Scooped by
Gilbert C FAURE
July 5, 2021 11:26 AM
|
Cancer remains one of the most challenging diseases, as many patients show limited
therapeutic response to treatment. Liquid biopsy is a minimally invasive method that
has the advantage of providing real-time disease information with the least damage
to cancer patients.
|
|
Scooped by
Gilbert C FAURE
November 20, 2020 3:00 AM
|
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions.
|
|
Scooped by
Gilbert C FAURE
August 8, 2020 9:55 AM
|
Enumeration and characterization of circulating tumor cells (CTC) hold the promise of a real time liquid biopsy. They are however present in a large b…
|
|
Scooped by
Gilbert C FAURE
April 4, 2020 3:43 AM
|
Metastases and cancer recurrence are the main causes of cancer death. Circulating Tumor Cells (CTCs) and disseminated tumor cells are the drivers of cancer cell dissemination. The assessment of CTCs’ clinical role in early metastasis prediction, diagnosis, and treatment requires more information about their biology, their roles in cancer dormancy, and immune evasion as well as in therapy resistance. Indeed, CTC functional and biochemical phenotypes have been only partially characterized using murine metastasis models and liquid biopsy in human patients. CTC detection, characterization, and enumeration represent a promising tool for tailoring the management of each patient with cancer. The comprehensive understanding of CTCs will provide more opportunities to determine their clinical utility. This review provides much-needed insights into this dynamic field of translational cancer research.
|
|
Scooped by
Gilbert C FAURE
March 28, 2020 2:46 PM
|
Abstract
Background
Genomic rearrangement in anaplastic lymphoma kinase (ALK) gene occurs in 3−7% of patients with non-small-cell lung cancer (NSCLC). The detection of this alteration is crucial as ALK positive NSCLC patients benefit from ALK inhibitors, which improve both the patient's quality of...
|
|
Scooped by
Gilbert C FAURE
November 25, 2019 12:11 PM
|
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to define the technical feasibility of a high-intensity sequencing assay of cfDNA and matched white blood cell DNA covering a large genomic region (508 genes; 2 megabases; >60,000× raw depth) in a prospective study of 124 patients with metastatic cancer, with contemporaneous matched tumor tissue biopsies, and 47 controls without cancer. The assay displayed high sensitivity and specificity, allowing for de novo detection of tumor-derived mutations and inference of tumor mutational burden, microsatellite instability, mutational signatures and sources of somatic mutations identified in cfDNA. The vast majority of cfDNA mutations (81.6% in controls and 53.2% in patients with cancer) had features consistent with clonal hematopoiesis. This cfDNA sequencing approach revealed that clonal hematopoiesis constitutes a pervasive biological phenomenon, emphasizing the importance of matched cfDNA–white blood cell sequencing for accurate variant interpretation. Ultra-sensitive cell-free DNA (cfDNA) sequencing uncovers clonal hematopoiesis as a major source of somatic cfDNA variants in healthy individuals and patients with cancer, and underscores the importance of matched white blood cell DNA sequencing in liquid biopsy procedures.
|
